Oak Associates’s GSK GSK Stock Holding History

Oak Associates’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-124,284	Closed	-$3.66M	–	147
2022 Q3	$3.66M	Hold	124,284	–	–	0.31%	52
2022 Q2	$6.76M	Sell	124,284 -16	-0%	-$883	0.53%	42
2022 Q1	$6.77M	Hold	124,300	–	–	0.41%	47
2021 Q4	$6.85M	Hold	124,300	–	–	0.36%	51
2021 Q3	$5.94M	Hold	124,300	–	–	0.34%	52
2021 Q2	$6.19M	Sell	124,300 -12,000	-9%	-$577K	0.35%	51
2021 Q1	$6.08M	Sell	136,300 -18,636	-12%	-$846K	0.36%	49
2020 Q4	$7.13M	Sell	154,936 -14,516	-9%	-$667K	0.43%	49
2020 Q3	$7.97M	Sell	169,452 -14,392	-8%	-$721K	0.53%	47
2020 Q2	$9.37M	Sell	183,844 -108,832	-37%	-$5.58M	0.63%	43
2020 Q1	$13.9M	Sell	292,676 -12,468	-4%	-$665K	1.14%	29
2019 Q4	$17.9M	Sell	305,144 -36	-0%	-$2K	1.06%	34
2019 Q3	$16.3M	Buy	305,180 +60	+0%	+$3.09K	1%	33
2019 Q2	$15.3M	Hold	305,120	–	–	0.95%	36
2019 Q1	$15.9M	Sell	305,120 -524	-0.2%	-$26.2K	0.97%	36
2018 Q4	$14.6M	Buy	305,644 +15,336	+5%	+$755K	1.03%	34
2018 Q3	$14.6M	Buy	290,308 +21,200	+8%	+$1.08M	0.89%	40
2018 Q2	$13.6M	Sell	269,108 -208	-0.1%	-$10.5K	0.91%	38
2018 Q1	$13.2M	Buy	269,316 +1,636	+0.6%	+$76.2K	0.92%	38
2017 Q4	$11.9M	Buy	267,680 +724	+0.3%	+$33.4K	0.84%	45
2017 Q3	$13.5M	Buy	266,956 +17,916	+7%	+$909K	1%	35
2017 Q2	$13.4M	Buy	249,040 +22,576	+10%	+$1.2M	1.01%	32
2017 Q1	$11.9M	Buy	226,464 +84,464	+59%	+$4.28M	0.95%	35
2016 Q4	$6.84M	Buy	142,000 +87,280	+160%	+$4.31M	0.67%	39
2016 Q3	$2.74M	Hold	54,720	–	–	0.28%	75
2016 Q2	$2.96M	Hold	54,720	–	–	0.36%	71
2016 Q1	$2.77M	Hold	54,720	–	–	0.34%	70
2015 Q4	$2.76M	Buy	54,720 +6,480	+13%	+$330K	0.33%	70
2015 Q3	$2.32M	Buy	48,240 +11,760	+32%	+$612K	0.31%	75
2015 Q2	$1.9M	Buy	36,480 +6,240	+21%	+$351K	0.23%	92
2015 Q1	$1.74M	Hold	30,240	–	–	0.21%	94
2014 Q4	$1.62M	Hold	30,240	–	–	0.19%	96
2014 Q3	$1.74M	Hold	30,240	–	–	0.21%	92
2014 Q2	$2.02M	Hold	30,240	–	–	0.25%	86
2014 Q1	$2.02M	Hold	30,240	–	–	0.25%	81
2013 Q4	$2.02M	Buy	+30,240	New	+$1.96M	0.22%	82
2013 Q2	$1.95M	Buy	+31,280	New	+$1.99M	0.23%	74

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Oak Associates's GSK Position: Q4 2022 in Review

Oak Associates sold out of GSK (GSK) in Q4 2022, closing a stake of 124,284 shares — an estimated $3.66M sold.

Oak Associates first reported a position in GSK in Q2 2013 and held it in 37 quarters. The position peaked at $17.9M in Q4 2019. 813 funds tracked by Wall St. Rank hold GSK as of Q4 2022.

Oak Associates reported no remaining GSK position as of Q4 2022 after selling out during the quarter.
Oak Associates sold 124,284 GSK shares in Q4 2022, an estimated $3.66M.
Oak Associates first reported a position in GSK in Q2 2013 and held it in 37 quarters.
Oak Associates's GSK position peaked at $17.9M in Q4 2019.
813 funds tracked by Wall St. Rank held GSK as of Q4 2022.

Based on Oak Associates's 13F filing for Q4 2022, filed 9 Feb 2023.